Stacey J. Adam

Stacey J. Adam

Auto-generated profile, based on publicly available information

Stacey J. Adam

Foundation for the National Institutes of Health, North Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KAKenneth C. Anderson
Kenneth C. Anderson
DADaniel Auclair
Daniel Auclair
SAStacey J. Adam
Stacey J. Adam
AAAmit Agarwal
Amit Agarwal
MAMelissa Anderson
Melissa Anderson
SKShaji K. Kumar
Shaji K. Kumar
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy–based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid–based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individual patient and clinical trial level meta-analyses have already shown and will continue to assess the potential of MRD as a surrogate for patient outcome. Given all this progress, it is not surprising that a number of clinicians are now considering using MRD to inform real-world clinical care of patients across the spectrum from smoldering myeloma to relapsed refractory multiple myeloma, with each disease setting presenting key challenges and questions that will need to be addressed through clinical trials. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented, and novel MRD-driven biomarker strategies are essential to accelerate innovative clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes.

10 January 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
SSShawn M. Sweeney
Shawn M. Sweeney
HHHisham K. Hamadeh
Hisham K. Hamadeh
NANatalie Abrams
Natalie Abrams
SAStacey J. Adam
Stacey J. Adam
SBSara Brenner
Sara Brenner
SSSudhir Srivastava
Sudhir Srivastava
Big data in healthcare can enable unprecedented understanding of diseases and their treatment, particularly in oncology. These data may include electronic health records, medical imaging, genomic sequencing, payor records, and data from pharmaceutical research, wearables, and medical devices. The ability to combine datasets and use data across many analyses is critical to the successful use of big data and is a concern for those who generate and use the data. Interoperability and data quality continue to be major challenges when working with different healthcare datasets. Mapping terminology across datasets, missing and incorrect data, and varying data structures make combining data an onerous and largely manual undertaking. Data privacy is another concern addressed by the Health Insurance Portability and Accountability Act, the Common Rule, and the General Data Protection Regulation. The use of big data is now included in the planning and activities of the FDA and the European Medicines Agency. The willingness of organizations to share data in a precompetitive fashion, agreements on data quality standards, and institution of universal and practical tenets on data privacy will be crucial to fully realizing the potential for big data in medicine.

1 September 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
LLLisa LaVange
Lisa LaVange
SAStacey J. Adam
Stacey J. Adam
JCJudith S. Currier
Judith S. Currier
EHElizabeth S. Higgs
Elizabeth S. Higgs
LRLora A. Reineck
Lora A. Reineck
AGACTIV Therapeutics-Clinical Working Group*
ACTIV Therapeutics-Clinical Working Group*
Despite the development of highly effective SARS-CoV-2 vaccines, there remains a great need for effective treatment of COVID-19. Through a public–private partnership in the United States, a system ... Working in an unprecedented time frame, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership developed and launched 9 master protocols between 14 Apri...

7 October 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
DSDelaney K. Sullivan
Delaney K. Sullivan
ADAnja Deutzmann
Anja Deutzmann
JYJosiah Yarbrough
Josiah Yarbrough
MKMaya S. Krishnan
Maya S. Krishnan
AGArvin M. Gouw
Arvin M. Gouw
DFDean W. Felsher
Dean W. Felsher

10 January 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
SSShawn M. Sweeney
Shawn M. Sweeney
HHHisham K. Hamadeh
Hisham K. Hamadeh
NANatalie Abrams
Natalie Abrams
SAStacey J. Adam
Stacey J. Adam
SBSara Brenner
Sara Brenner
SSSudhir Srivastava
Sudhir Srivastava
The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are challenges in organizing, sharing, integrating, and making these data readily accessible to the research community. This review presents five case studies illustrating various successful approaches to addressing such challenges. These efforts are CancerLinQ, the American Association for Cancer Research Project GENIE, Project Data Sphere, the National Cancer Institute Genomic Data Commons, and the Veterans Health Administration Clinical Data Initiative. Critical factors in the development of these systems include attention to the use of robust pipelines for data aggregation, common data models, data deidentification to enable multiple uses, integration of data collection into physician workflows, terminology standardization and attention to interoperability, extensive quality assurance and quality control activity, incorporation of multiple data types, and understanding how data resources can be best applied. By describing some of the emerging resources, we hope to inspire consideration of the secondary use of such data at the earliest possible step to ensure the proper sharing of data in order to generate insights that advance the understanding and the treatment of cancer.

26 April 2006 in Cell Cycle
Verified
Journal Article
Closed access
SKS. DiSean Kendall
S. DiSean Kendall
SAStacey J. Adam
Stacey J. Adam
CCChristopher M. Counter
Christopher M. Counter
Cancer models are vital to cancer biology research, and multiple cancer models are currently available that utilize either murine or human cells, each with particular strengths and weaknesses. The ability to transform primary human cells into tumors through the expression of specific transgenes offers many advantages as a cancer model, including genetic malleability and the ability to transform specific cell types. Until recently, the conversion of primary human cells into tumors through transgene expression required the use of viral genetic elements, which unfortunately adds uncertainty regarding which cancer pathways are affected and how they are affected. In recent years multiple reports have described the transformation of primary human cells into tumors using only mammalian transgenes. This review focuses on these five cancer models, comparing the different cell types which were transformed into tumors and which transgenes were expressed, as well as the cancer pathways affected in the disparate model...